Antibody Drug Conjugate News and Research

RSS

Lab-Scale Clarification of Mammalian Cell Cultures Expressing Recombinant Antibodies

Tina Stoschek and Marcus Gerlach discuss maximizing mAb generation using lab-scale clarification of cell cultures expressing recombinant antibodies.

From Sartorius 23 Jan 2019

AI pathology diagnostic tool developed using deep learning technology from Olympus

Since 2017, Olympus Corporation has participated in a joint research program that has the potential to help streamline the workload of clinical pathologists, called “A New Approach to Develop Computer-Aided Diagnosis Using Artificial Intelligence (AI) for Gastric Biopsy Specimens”.

From Evident Corporation - Life Sciences 18 Oct 2018

Personalized goal setting to improve dementia care

Dementia is a health condition that affects your memory in ways that can make it difficult to carry out your usual daily tasks. The most common cause of dementia is Alzheimer's disease, which causes abnormal changes that kill brain cells.

11 Oct 2018

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

1 Oct 2018

Forbius receives $18.75 million grant from CPRIT for Phase 2a development of AVID100

Forbius announced today that it has been awarded a Product Development grant totaling $18.75 million from the Cancer Prevention and Research Institute of Texas.

25 Aug 2018

New Spectrum digitizers are ideal for use in multi-channel applications

Spectrum Instrumentation has added twelve new products to its family of LXI-based digitizerNETBOX data acquisition instruments. Designed specifically for situations where multiple signals need to be acquired, stored and analyzed, users can select from models that provide 24, 32, 40 or even 48 fully synchronized channels.

From Spectrum Instrumentation GmbH 27 Jul 2018

Minakem's new high-class production facility extends capacity to develop and manufacture HPAPI compounds

Minakem, the CDMO division of Minafin, specialized in custom development and manufacturing of building blocks, GMP intermediates and Active Pharmaceutical Ingredients, today announces it is in the final qualification run to open a new closed-controlled environment high containment production facility in August.

22 Jun 2018

Targeted 'click-to-release' chemotherapy leads to potent antitumor activity in mice

Antibody Drug Conjugates are relatively new anti-cancer drugs. They consist of an antibody to which a cell-killing molecule (chemotherapy) is attached. Antibodies can recognize and bind to certain receptors (the 'hands' on the outside of a cell) in a very targeted way.

4 May 2018

Abzena selects Sartorius Stedim Biotech as preferred equipment supplier in the U.S

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.

From Sartorius 9 Feb 2018

UCSF researchers find new way to attack common drivers of 'undruggable' cancers

Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer.

24 Jan 2018

Researchers use novel imaging technique for precise assessment of spinal degeneration

Research by a Barrow Neurological Institute neurosurgery team on novel imaging technique assessment of patients with lumbar spine degeneration was published in the Aug. 28 issue of PLOS ONE.

20 Oct 2017

Researchers identify protein that offers likely target for treating high-risk pediatric cancers

Oncology researchers studying high-risk children's cancers have identified a protein that offers a likely target for immunotherapy--harnessing the immune system in medical treatments. In cell cultures and animal models, a potent drug attached to an antibody selectively zeroes in on cancer cells without harming healthy cells.

11 Sep 2017

NIH funds BU ADC with $5.4 million grant to advance research on Alzheimer's disease

The National Institutes of Health/National Institute on Aging has awarded the Boston University Alzheimer's Disease Center a three-year, $5.4 million grant to continue research on ways to reduce the human and economic costs of Alzheimer's disease (AD) through the advancement of knowledge.

26 Aug 2017

History of traumatic brain injury not related to cognitive decline, study shows

Although much research has examined traumatic brain injury (TBI) as a possible risk factor for later life dementia from neurodegenerative diseases such as Alzheimer's disease (AD), little is known regarding how TBI influences the rate of age-related cognitive change.

5 Jul 2017

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

New research presented at the American Society of Clinical Oncology 53rd Annual Meeting in Chicago shows that a previously untested combination of a monoclonal antibody-drug conjugate with a common chemotherapy agent has a high complete-response rate in children and young adults with relapsed or refractory Hodgkin lymphoma.

6 Jun 2017

Some types of cancers are heavily dependent on sugar, study shows

In a new study, scientists at The University of Texas at Dallas have found that some types of cancers have more of a sweet tooth than others.

26 May 2017

Antibody drug conjugate could hold promise in improving treatment for childhood ALL

Researchers at The University of Manchester have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia.

From The University of Manchester 19 May 2017

TSRI researchers develop novel drug delivery method for treating cancers

Scientists from the Florida campus of The Scripps Research Institute have developed a new drug delivery method that produces strong results in treating cancers in animal models, including some hard-to-treat solid and liquid tumors.

16 Mar 2017

Bruker showcases innovative high-performance systems and high-value analytical solutions at Pittcon 2017

Bruker (NASDAQ: BRKR) is showcasing a selection of innovative high-performance systems and high-value analytical solutions at Pittcon 2017 (www.pittcon.org), with an emphasis on pharma and applied markets, as well as on nano-materials research and microscopy.

From Bruker BioSpin - NMR, EPR and Imaging 7 Mar 2017

TSRI scientists receive $3.3 million NIH grant to create new breast cancer treatments

A pair of scientists from the Florida campus of The Scripps Research Institute have been awarded up to $3.3 million from the National Cancer Institute of the National Institutes of Health to create the next generation of breast cancer treatments for the thousands of patients whose current treatment options are limited.

14 Feb 2017